Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 3, 2014, Pages 295-308

  Giralt, Sergio ^a   Costa, Luciano ^b   Schriber, Jeffrey ^c   DiPersio, John ^d   Maziarz, Richard ^e   McCarty, John ^f   Shaughnessy, Paul ^g   Snyder, Edward ^h   Bensinger, William ⁱ   Copelan, Edward ^j   Hosing, Chitra ^k   Negrin, Robert ^l   Petersen, Finn Bo ^m   Rondelli, Damiano ⁿ   Soiffer, Robert ^o   Leather, Helen ^p   Pazzalia, Amy ^p   Devine, Steven ^q  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Virginia G Piper Cancer Center   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g TEXAS TRANSPLANT INSTITUTE   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j LEVINE CANCER INSTITUTE   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Intermountain Blood and Marrow Transplant Program   (United States)

ⁿ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^o HARVARD MEDICAL SCHOOL   (United States)

^p UNIVERSITY OF FLORIDA   (United States)

^q OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

Chemomobilization; Growth factors; Mobilization; Mobilization failure; Optimal collection; Plerixafor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1;

ALGORITHM; APHERESIS; APHERESIS DEVICE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD VOLUME; CONSENSUS; HEALTH CARE COST; HODGKIN DISEASE; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAFETY; STEADY STATE; STEM CELL MOBILIZATION; TARGET CELL;

CHEMOMOBILIZATION; GROWTH FACTORS; MOBILIZATION; MOBILIZATION FAILURE; OPTIMAL COLLECTION; PLERIXAFOR;

GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84896691513     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.013     Document Type: Review

References (200)

1. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. JClin Oncol 2006, 24:929-936.
2. Attal M., Harousseau J., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. NEngl J Med 2003, 349:2495-2502.
3. Attal M., Harousseau J., Stoppa A., et al. Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. NEngl J Med 1996, 335:91-97.
4. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. NEngl J Med 2003, 348:1875-1883.
5. Bladé J., Rosiñol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106:3755-3759.
6. Fermand J., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. JClin Oncol 2005, 23:9227-9233.
7. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004, 104:3052-3057.
8. Segeren C.M., Sonneveld P., van der Holt B., et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003, 101:2144-2151.
9. Oliansky D.M., Czuczman M., Fisher R.I., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011, 17:20-47.
10. Oliansky D.M., Gordon L.I., King J., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010, 16:443-468.
11. Copelan E.A. Hematopoietic stem-cell transplantation. NEngl J Med 2006, 354:1813-1826.
12. Center for International Blood and Marrow Transplantation Research. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2011. Available from:. Accessed March 11,2012. http://www.cibmtr.org/.
13. Sheppard D., Bredeson C., Allan D., Tay J. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2012, 18:1191-1203.
14. Kessinger A., Armitage J.O., Landmark J.D., Weisenburger D.D. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986, 14:192-196.
15. Juttner C.A., To L.B., Ho J.Q., et al. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Transplant Proc 1988, 20:40-42.
16. Gianni A.M., Siena S., Bregni M., et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989, 334:580-585.
17. Socinski M.A., Cannistra S.A., Elias A., et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988, 331:1194-1198.
18. Lane T., Law P., Maruyama M., et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995, 85:275-282.
19. Petit I., Szyper-Kravitz M., Nagler A., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002, 3:687-694.
20. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
21. Alegre A., Tomas J.F., Martinez-Chamorro C., et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997, 20:211-217.
22. Chao N.J., Grima D.T., Carrum G., et al. Chemo-mobilization provides superior mobilization and collection in autologous stem cell transplants but with less predictability and at a higher cost. ASH Annual Meeting Abstracts. Blood 2011, 118:4048.
23. Desikan K.R., Barlogie B., Jagannath S., et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. JClin Oncol 1998, 16:1547-1553.
24. Desikan K.R., Tricot G., Munshi N.C., et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001, 112:242-247.
25. Dingli D., Nowakowski G.S., Dispenzieri A., et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006, 6:384-388.
26. Hoggatt J., Pelus L.M. Hematopoietic stem cell mobilization with agents other than G-CSF. Methods Mol Biol 2012, 904:49-67.
27. Harvey R.D., Kaufman J.L., Johnson H.R., et al. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biol Blood Marrow Transplant 2013, 19:1393-1395.
28. Larochelle A., Krouse A., Metzger M., et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006, 107:3772-3778.
29. Fruehauf S., Veldwijk M.R., Seeger T., et al. Acombination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European Phase II study. Cytotherapy 2009, 11:992-1001.
30. Cuzzola M., Spiniello E., Martino M., et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor mobilize different cell populations based on immunophenotype and global gene experssion signatures [abstract P1082]. Bone Marrow Transplant 2011, 46(Suppl 1):S335.
31. Devine S.M., Vij R., Rettig M., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
32. Varmavuo V., Mäntymaa P., Kuittinen T., et al. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte colony-stimulating factor. Transfusion 2012, 52:1785-1791.
33. + cells and dendritic cells by AMD3100 plus granulocyte colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007, 16:657-666.
34. Fruehauf S., Seeger T., Maier P., et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006, 34:1052-1059.
35. Hess D.A., Bonde J., Craft T.C., et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony-stimulating factor. Biol Blood Marrow Transplant 2007, 13:398-411.
36. + cells mobilized by G-CSF and plerixafor. Exp Hematol 2011, 39:795-805.
37. Giralt S., Stadtmauer E.A., Harousseau J.L., et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009, 23:1904-1912.
38. Kumar S., Giralt S., Stadtmauer E.A., et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009, 114:1729-1735.
39. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. JClin Oncol 1995, 13:2547-2555.
40. Weaver C., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995, 86:3961-3969.
41. Oran B., Malek K., Sanchorawala V., et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005, 35:567-575.
42. + cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999, 24:1279-1283.
43. Carral A., de la Rubia J., Martin G., et al. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplant 2002, 29:825-832.
44. + cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998, 91:3148-3155.
45. Glaspy J.A., Shpall E.J., LeMaistre C.F., et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997, 90:2939-2951.
46. + cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011, 17:1146-1153.
47. Benedetti G., Patoia L., Giglietti A., et al. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Bone Marrow Transplant 1999, 24:971-979.
48. Snyder E.L., Baril L., Cooper D.L., et al. Invitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation. Transfusion 2000, 40:961-967.
49. Snyder E.L., O'Donnell L., Dengler T.J., et al. Exvivo evaluation of PBMNCs collected with a new cell separator. Transfusion 2001, 41:940-949.
50. Apheresis: principles and practice 2010, AABB Press, Bethesda (MD). 3rd ed. B.C. McLeod (Ed.).
51. McGee D.C., Gould M.K. Preventing complications of central venous catheterization. NEngl J Med 2003, 348:1123-1133.
52. Cecyn K.Z., Seber A., Ginani V.C., et al. Large-volume leukapheresis for peripheral blood progenitor cell collection in low body weight pediatric patients: a single-center experience. Transfus Apher Sci 2005, 32:269-274.
53. Bojanic I., Dubravcic K., Batinic D., et al. Large volume leukapheresis: efficacy and safety of processing patient's total blood volume six times. Transfus Apher Sci 2011, 44:139-147.
54. + collection efficiency as a function of blood volumes processed in pediatric autologous peripheral blood stem cell collection. JClin Apher 2011, 26:131-137.
55. Gašová Z., Marinov I., Vodvářková Š., et al. PBPC collection techniques: standard versus large-volume leukapheresis (LVL) in donors and in patients. Transfus Apher Sci 2005, 32:167-176.
56. Gašová Z., Bhuiyan-Ludvíková Z., Böhmová M., et al. PBPC collections: management, techniques and risks. Transfus Apher Sci 2010, 43:237-243.
57. Malachowski M.E., Comenzo R.L., Hillyer C.D., et al. Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 1992, 32:732-735.
58. + precount in predicting successful collection. Int J Artif Organs 1999, 22:334-341.
59. Murea S., Goldschmidt H., Hahn U., et al. Successful collection and transplantation of peripheral blood stem cells in cancer patients using large-volume leukaphereses. JClin Apher 1996, 11:185-194.
60. Accorsi P., Dell'Isola M., Bonfini T., et al. Large-volume leukapheresis with AMICUS cell separator in peripheral blood stem cell autologous transplant. Transfus Apher Sci 2001, 24:79-83.
61. + subsets during apheresis. JCancer Res Clin Oncol 2002, 128:19-28.
62. Humpe A., Riggert J., Munzel U., et al. Aprospective, randomized, sequential, crossover trial of large-volume versus normal-volume leukapheresis procedures: effect on progenitor cells and engraftment. Transfusion 1999, 39:1120-1127.
63. Smolowicz A.G., Villman K., Tidefelt U. Large-volume apheresis for the harvest of peripheral blood progenitor cells for autologous transplantation. Transfusion 1997, 37:188-192.
64. + cells. Transfusion 2005, 45:248-253.
65. Cassens U., Barth I.M., Baumann C., et al. Factors affecting the efficacy of peripheral blood progenitor cells collections by large-volume leukaphereses with standardized processing volumes. Transfusion 2004, 44:1593-1602.
66. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-hodgkin's lymphoma. JClin Oncol 2009, 27:4767-4773.
67. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
68. Lin J.S., Burgstaler E.A., Pineda A.A., Gertz M.A. Effects of whole blood flow rates on mononuclear cell yields during peripheral blood stem cell collection using Fenwal CS 3000 Plus. JClin Apher 1995, 10:7-11.
69. Humpe A., Riggert J., Munzel U., Köhler M. Aprospective, randomized, sequential crossover trial of large-volume versus normal-volume leukapheresis procedures: effects on serum electrolytes, platelet counts, and other coagulation measures. Transfusion 2000, 40:368-374.
70. Bolan C.D., Leitman S.F. Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. Blood 2002, 99:1878.
71. Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009, 43:181-195.
72. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:719-724.
73. Gertz M.A., Wolf R.C., Micallef I.N., Gastineau D.A. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010, 45:1396-1403.
74. Paripati H., Stewart A.K., Cabou S., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008, 22:1282-1284.
75. Roberts C., Sabo R., Shickle L., et al. Cost-effective stem cell mobilization: a novel early plerixafor salvage strategy is optimally resource-effective compared to chemotherapy, G-CSF or initial plerixafor strategies [abstract O378]. Bone Marrow Transplant 2011, 46(Suppl 1):S60-S61.
76. Russell N., Mesters R., Schubert J., et al. Aphase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008, 93:405-412.
77. Mazumder A., Kaufman J., Niesvizky R., et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008, 22:1280-1281. author reply 1281-1282.
78. Micallef I.N., Apostolidis J., Rohatiner A.Z., et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-hodgkin's lymphoma. Hematol J 2000, 1:367-373.
79. Stiff P.J. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999, 23(Suppl 2):S29-S33.
80. Hosing C., Saliba R.M., Ahlawat S., et al. Poor hematopoietic stem cell mobilizers: a single-institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009, 84:335-337.
81. Wuchter P., Ran D., Bruckner T., et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010, 16:490-499.
82. Haas R., Mohle R., Fruhauf S., et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994, 83:3787-3794.
83. Popat U., Saliba R., Thandi R., et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009, 15:718-723.
84. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
85. Cavallo F., Bringhen S., Milone G., et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 2011, 25:1627-1631.
86. Tournilhac O., Cazin B., Leprètre S., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004, 103:363-365.
87. Waterman J., Rybicki L., Bolwell B., et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 2011, 47:488-493.
88. Ferraro F., Lymperi S., Méndez-Ferrer S., et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011, 3:104ra101.
89. Hoelig K., Kroschinsky F., Kramer M., et al. Predictors for the efficacy of peripheral blood progenitor cell (PBPC) collection-results from 4050 harvests performed in a single centre. ASH Annual Meeting Abstracts. Blood 2008, 112:4131.
90. + cells to treat subjects with refractory chronic myocardial ischemia (CMI): factors influencing mobilization and apheresis. ASH Annual Meeting Abstracts. Blood 2009, 114:3227.
91. Jantunen E., Kuittinen T., Nousiainen T. Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-hodgkin's lymphoma?. Bone Marrow Transplant 2003, 32:569-573.
92. Sutherland D.R., Stewart A.K., Keating A. CD34 antigen: molecular features and potential clinical applications. Stem Cells 1993, 11(Suppl 3):50-57.
93. + hematopoietic stem and progenitor cells. Curr Protoc Cytom 2001, Unit 6.4. 10.1002/0471142956.cy0604s25.
94. + cell enumeration as a predictor of apheresis yield: an analysis of over 1000 collections. Biol Blood Marrow Transplant 2012, 18:763-772.
95. Costa L.J., Alexander E.T., Hogan K.R., et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011, 46:64-69.
96. Abhyankar S., Dejarnette S., Aljitawi O., et al. Arisk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2011, 47:483-487.
97. LaPorte J., Solomon S.R., Bashey A., et al. An effective hematopoietic stem cell mobilization algorithm for adding plerixafor to G-CSF for multiple myeloma patients undergoing autologous transplantation. ASH Annual Meeting Abstracts. Blood 2011, 118:4389.
98. Micallef I.N., Sinha S., Gastineau D.A., et al. Cost-effectiveness analysis of a risk-adapted algorithm for plerixafor use in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013, 19:87-93.
99. Micallef I.N., Inwards D.J., Dispenzieri A., et al. Arisk-adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2010, 16(Suppl 2):S197-S198.
100. Narayanasami U., Kanteti R., Morelli J., et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001, 98:2059-2064.
101. Dazzi C., Cariello A., Rosti G., et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?. Leuk Lymphoma 2000, 39:301-310.
102. Glaspy J.A. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 1999, 23(Suppl 2):S21-S27.
103. Kanteti R., Miller K., McCann J., et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Bone Marrow Transplant 1999, 24:473-481.
104. Zeller W., Gutensohn K., Stockschlader M., et al. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 1996, 17:709-713.
105. Weaver C.H., Birch R., Greco F.A., et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998, 100:338-347.
106. Sheridan W.P., Begley C.G., To L.B., et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994, 14:105-111.
107. Stiff P., Gingrich R., Luger S., et al. Arandomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000, 26:471-481.
108. Weaver C.H., Schulman K.A., Wilson-Relyea B., et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. JClin Oncol 2000, 18:43-53.
109. Arora M., Burns L.J., Barker J.N., et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004, 10:395-404.
110. Hosing C., Qazilbash M.H., Kebriaei P., et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 2006, 133:533-537.
111. Randomized, double-blind study of peripheral blood progenitor cell (PBPC) mobilization by pegfilgrastim or filgrastim for autologous transplantation in subjects with Hodgkin's or non-Hodgkin's lymphoma. Available from:. Accessed. http://download.veritasmedicine.com/REGFILES/amgen/20020112.pdf.
112. Costa L.J., Kramer C., Hogan K.R., et al. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 2012, 52:2375-2381.
113. Bruns I., Steidl U., Kronenwett R., et al. Asingle dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006, 46:180-185.
114. Zappasodi P., Nosari A.M., Astori C., et al. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion 2008, 48:857-860.
115. Steidl U., Fenk R., Bruns I., et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005, 35:33-36.
116. Fruehauf S., Klaus J., Huesing J., et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007, 39:743-750.
117. Isidori A., Tani M., Bonifazi F., et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005, 90:225-231.
118. Putkonen M., Rauhala A., Pelliniemi T.T., Remes K. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. Ann Hematol 2009, 88:673-680.
119. Simona B., Cristina R., Luca N., et al. Asingle dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci 2010, 43:321-326.
120. Tricot G., Barlogie B., Zangari M., et al. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica 2008, 93:1739-1742.
121. Cesaro S., Zanazzo A.G., Frenos S., et al. Aphase II study on the safety and efficacy of a single dose of pegfilgrastim for mobilization and transplantation of autologous hematopoietic stem cells in pediatric oncohematology patients. Transfusion 2011, 51:2480-2487.
122. Hiwase D.K., Bollard G., Hiwase S., et al. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007, 9:539-547.
123. Hamadani M., Kochuparambil S.T., Osman S., et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant 2012, 18:1128-1135.
124. Sizemore C.A., Laporte J., Holland H.K., et al. Acomparison of toxicity and mobilization efficacy following two different doses of cyclophosphamide for mobilization of hematopoietic stem cells in non-Hodgkin's lymphoma patients. Biol Blood Marrow Transplant 2010, 16(Suppl 2):S206.
125. Sizemore C.A., LaPorte J., Sanacore M., et al. Acomparison of toxicity and mobilization efficacy following two different doses of cyclophosphamide for mobilization of hematopoietic stem cells in multiple myeloma patients. ASH Annual Meeting Abstracts. Blood 2009, 114:4229.
126. Damon L.E., Johnson J.L., Niedzwiecki D., et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. JClin Oncol 2009, 27:6101-6108.
127. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with invivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
128. Bacon W.A., Long G.D., Rizzieri D.A., et al. Impact of high-dose cyclophosphamide on the outcome of autologous stem cell transplant in patients with newly diagnosed multiple myeloma, ASH Annual Meeting Abstracts. Blood 2011, 118:4127.
129. Flomenberg N., Devine S.M., DiPersio J.F., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
130. Isola L., Banoff K.M., Kim S.S. Pharmacoeconomic impact of upfront use plerixafor for autologous stem cell mobilization in multiple myeloma patients. ASH Annual Meeting Abstracts. Blood 2011, 118:2075.
131. Li J., Hamilton E., Vaughn L., et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011, 51:2175-2182.
132. Perkins J., Bookout R., Sapiro J., et al. Retrospective comparison of secondary mobilization strategies in candidates for autologous hematopoietic cell transplantion with A focus on resource utilization: Plerixafor+ G-CSF versus other regimens. Biol Blood Marrow Transplant 2010, 16(Suppl 2):S197.
133. + cells in autologous hematopoietic cell transplant candidates, ASH Annual Meeting Abstracts. Blood 2011, 118:4060.
134. Shaughnessy P., Islas-Ohlmayer M., Murphy J., et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011, 17:729-736.
135. Adel N.G., Duck E., Collum K., et al. Cost analysis of using plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC), ASH Annual Meeting Abstracts. Blood 2011, 118:4059.
136. Campen C.J., Armstrong E.P., Christian J.A., et al. Comparative cost-effectiveness of plerixafor plus granulocyte-colony stimulating factor versus cyclophosphamide plus granulocyte-colony stimulating for autologous peripheral blood stem cell mobilization in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2010, 16(Suppl 2):S206.
137. Vishnu P., Roy V., Paulsen A., Zubair A.C. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012, 52:55-62.
138. Costa L.J., Miller A.N., Alexander E.T., et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011, 46:523-528.
139. Dugan M.J., Maziarz R.T., Bensinger W.I., et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010, 45:39-47.
140. Attolico I., Pavone V., Ostuni A., et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012, 18:241-249.
141. Nimmagadda S., Sweiss K., Mahmud N., et al. Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF. Bone Marrow Transplant 2010, 45:1121-1122.
142. Basak G.W., Urbanowska E., Boguradzki P., et al. Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure. Ann Transplant 2010, 15:61-67.
143. Basak G.W., Mikala G., Koristek Z., et al. Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. Leuk Lymphoma 2011, 52:1711-1719.
144. Jantunen E., Kuittinen T., Mahlamäki E., et al. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single-centre experience. Eur J Haematol 2011, 86:299-304.
145. Jantunen E., Varmavuo V., Kuittinen T., et al. Effect of plerixafor on graft lymphocyte subsets in NHL patients mobilizing poorly with chemotherapy plus G-CSF. ASH Annual Meeting Abstracts. Blood 2011, 118:1929.
146. + subclasses of blood stem cell grafts collected after plerixafor injection in non-Hodgkin lymphoma (NHL) patients mobilizing poorly with chemotherapy plus G-CSF. ASH Annual Meeting Abstracts. Blood 2011, 118:2990.
147. Kochuparambil S.T., Mebel E.R., DeRemer D.L., et al. Optimizing the efficacy of plerixafor as a salvage option in poor mobilizers following chemotherapy plus G-CSF mobilization. Biol Blood Marrow Transplant 2011, 17(Suppl 2):S208-S209.
148. + cell collection when added to growth factor and plerixafor in patients who are poor mobilizers. ASH Annual Meeting Abstracts. Blood 2011, 118:4388.
149. Awan F.T., Kochuparambil S.T., Deremer D., et al. Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization. JOncol 2012, 2012:931071.
150. Vives S., Sancho J., Almazán F., et al. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma. JClin Apher 2012, 27:260-262.
151. + counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition. Transfus Apher Sci 2012, 46:257-262.
152. Costa L.J., Abbas J., Hogan K.R., et al. Growth factor plus preemptive ("just-in-time") plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 2012, 47:1403-1408.
153. Malard F., Kröger N., Gabriel I.H., et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012, 18:314-317.
154. Mark T., Stern J., Furst J.R., et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008, 14:795-798.
155. Micallef I.N., Ho A.D., Klein L.M., et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2011, 46:350-355.
156. Nazha A., Cook R., Vogl D.T., et al. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant 2011, 46:59-63.
157. Basak G.W., Jaksic O., Koristek Z., et al. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol 2011, 86:550-553.
158. Popat R., Oakervee H.E., Hallam S., et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008, 141:512-516.
159. Lu S., Wang J., Xu X., et al. Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol 2009, 89:34-38.
160. Kaufman J.L., Nooka A., Vrana M., et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Cancer 2010, 116:3143-3151.
161. Jakubowiak A.J., Kendall T., Al-Zoubi A., et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. JClin Oncol 2009, 27:5015-5022.
162. Corso A., Barbarano L., Mangiacavalli S., et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leuk Lymphoma 2010, 51:236-242.
163. Moreau P., Hulin C., Marit G., et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 2010, 24:1233-1235.
164. Ponisch W., Wiesler J., Leiblein S., et al. Successful mobilization of peripheral blood stem cells after intensive bendamustine pre-treatment in patients with multiple myeloma. ASH Annual Meeting Abstracts. Blood 2010, 116:4439.
165. Ponisch W., Wiesler J., Wagner I., et al. Impact of bendamustine pretreatment on stem cell mobilization and autologous stem cell transplantation in patients with multiple myeloma. ASH Annual Meeting Abstracts. Blood 2011, 118:1933.
166. Burchardt C.A., Brugger W., Maschmeyer G., et al. Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible: results from the Phase III study of B-R versus CHOP-R (NHL 1-2003 trial) of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting Abstracts. Blood 2009, 114:2679.
167. Boeve S., Strupeck J., Creech S., Stiff P.J. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004, 33:997-1003.
168. Jantunen E., Kuittinen T. Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues. Eur J Haematol 2008, 80:287-295.
169. Vellenga E., Van Agthoven M., Croockewit A.J., et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: The HOVON 22 study. Br J Haematol 2001, 114:319-326.
170. Woronoff-Lemsi M.C., Arveux P., Limat S., et al. Cost-comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplant 1997, 20:975-982.
171. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
172. Duarte R.F., Shaw B.E., Marin P., et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011, 46:52-58.
173. Hubel K., Fresen M.M., Apperley J.F., et al. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients: a subgroup analysis of the European Consortium of Stem Cell Mobilization. Bone Marrow Transplant 2011, 47:1046-1050.
174. Micallef I.N., Stiff P.J., DiPersio J.F., et al. Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009, 15:1578-1586.
175. Hosing C., Smith V., Rhodes B., et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 2011, 51:1300-1313.
176. Kymes S., Pusic I., Lambert D.L., et al. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care 2012, 18:33-41.
177. Schroeder M.A., DiPersio J.F. Mobilization of hematopoietic stem and leukemia cells. JLeukoc Biol 2012, 91:47-57.
178. Nervi B., Ramirez P., Rettig M.P., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
179. Uy G.L., Rettig M.P., Motabi I.H., et al. Aphase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012, 119:3917-3924.
180. Welschinger R., Liedtke F., Basnett J., et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol 2013, 41:293-302.e1.
181. Azab A.K., Runnels J.M., Pitsillides C., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351.
182. Fruehauf S., Ehninger G., Hubel K., et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010, 45:269-275.
183. Tricot G., Cottler-Fox M.H., Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010, 45:63-68.
184. Anagnostopoulos A., Aleman A., Yang Y., et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant 2004, 33:623-628.
185. Demirkazik A., Kessinger A., Armitage J.O., et al. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant 2001, 28:207-212.
186. Kopp H.G., Yildirim S., Weisel K.C., et al. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. JCancer Res Clin Oncol 2009, 135:637-642.
187. DiPersio J.F., Ho A.D., Hanrahan J., et al. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011, 17:943-955.
188. Rettig M.P., Ansstas G., Dipersio J.F. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 2012, 26:34-53.
189. Bakanay S.M., Demirer T. Novel agents and approaches for stem cell mobilization in normal donors and patients. Bone Marrow Transplant 2011, 47:1154-1163.
190. Ramirez P., Rettig M.P., Uy G.L., et al. BIO5192, a small-molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009, 114:1340-1343.
191. + peripheral blood progenitor cells after high- dose chemotherapy for patients with advanced multiple myeloma. Blood 1995, 86:390-397.
192. Pavone V., Gaudio F., Guarini A., et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002, 29:285-290.
193. Demirer T., Ayli M., Ozcan M., et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002, 116:468-474.
194. Gojo I., Guo C., Sarkodee-Adoo C., et al. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant 2004, 34:69-76.
195. Lefrere F., Zohar S., Ghez D., et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant 2006, 37:725-729.
196. Wood W.A., Whitley J., Moore D., et al. Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy. Biol Blood Marrow Transplant 2011, 17:141-146.
197. Wood W.A., Whitley J., Goyal R., et al. Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. Bone Marrow Transplant 2013, 48:771-776.
198. Shpall E.J., Wheeler C.A., Turner S.A., et al. Arandomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999, 93:2491-2501.
199. André M., Baudoux E., Bron D., et al. Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003, 43:50-57.
200. Weaver C.H., Schulman K.A., Buckner C.D. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001, 27(Suppl 2):S23-S29.